EG-30: clinical phase drug for AMD and Glaucoma EG-30 – the highlights: · Excellent safety profile in healthy volunteers and glaucoma patients• Low systemic exposure• No increase in IOP in glaucoma patients treated with EG-30 for 16days (eye drops)· Extensive safety a.....
[更多]
Additional information can be provided upon request
[更多]
| |<首頁 <-上一頁 下一頁-> 末頁>| |
